Praxis Precision Medicines FDA Application Accepted

Praxis Precision Medicines has received FDA acceptance for its New Drug Application (NDA) for Ulixacaltamide HCl, a treatment for essential tremor. The FDA has set a target action date of January 29, 2027, and has indicated that an advisory committee meeting is not expected. This acceptance marks a significant milestone in the drug development process, bringing Ulixacaltamide HCl closer to potential market availability for patients suffering from essential tremor.